Improving drug adherence in cancer patients through a multidisciplinary consultation program
Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
Centre Hospitalier Universitaire, Amiens · NCT04797143
This study tests whether a special consultation program can help cancer patients stick to their oral medication plans better by addressing their challenges.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens (other) |
| Locations | 1 site (Amiens) |
| Trial ID | NCT04797143 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of a multidisciplinary consultation program on drug adherence among patients undergoing their first oral anticancer treatment. It focuses on identifying barriers to adherence, such as access to medications, adverse effects, and complex regimens. The study measures drug adherence using the medication possession ratio (MPR) before and after implementing the consultation program. The goal is to enhance medication management and reduce healthcare costs associated with nonadherence.
Who should consider this trial
Good fit: Ideal candidates are French-speaking patients with newly diagnosed or relapsed cancer starting oral anticancer treatment.
Not a fit: Patients receiving hormone therapy only or those with severe psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve drug adherence and treatment outcomes for cancer patients on oral therapies.
How similar studies have performed: Other studies have shown that multidisciplinary approaches can improve medication adherence, suggesting potential success for this program.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * French speaking patients with a newly diagnosed or relapsed cancer, regardless of location and introduction of oral anticancer treatment Exclusion Criteria: * patients treated with hormone therapy only * Patient with severe psychiatric disorders * patient who does not speak the French language
Where this trial is running
Amiens
- CHU Amiens — Amiens, France (RECRUITING)
Study contacts
- Study coordinator: Aurélie terrier-lenglet, DR
- Email: terrier-lenglet.aurelie@chu-amiens.fr
- Phone: 0322087173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment, Drug Related Toxicity, Securing Medication Management, Multidisciplinary consultation program, adherence to oral anticancer treatment, drug related toxicity, securing medication management